Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $14.69 USD
Change Today +0.06 / 0.41%
Volume 99.8K
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

cutera inc (CUTR) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/29/15 - $16.37
52 Week Low
10/23/14 - $9.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CUTERA INC (CUTR)

cutera inc (CUTR) Related Bloomberg News

View More Bloomberg News

cutera inc (CUTR) Related Businessweek News

No Related Businessweek News Found

cutera inc (CUTR) Details

Cutera, Inc., a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems for practitioners worldwide. It offers products based on platforms, such as xeo, a multi-application platform on which a customer can purchase hand piece applications for the removal of unwanted hair, treatment of vascular lesions, and skin rejuvenation by treating discoloration, improving texture, reducing pore size, and treating fine lines and laxity; and Genesis Plus, a laser system for performing aesthetic skin procedures and for the temporary increase of clear nail in patients with onychomycosis, or toenail fungus. This system is also used to treat skin concerns, such as fine wrinkles, diffuse redness, and rosacea; and excel V, a vascular platform that treats the entire range of cosmetic vascular conditions. The company also offers truSculpt, a radio frequency platform designed for the non-invasive body contouring market; excel HR, a hair removal solution for various skin types; and enlighten, a laser system for tattoo removal and the treatment of benign pigmented lesions. In addition, its products include CoolGlide, Solera, and a third-party sourced system, myQ for the Japanese market. Further, the company provides post-warranty services through extended service contracts or direct billing; and sells Titan hand piece refills and marketing brochures through the Internet, as well as dermal fillers and cosmeceuticals. It markets and sells its products through direct sales force to plastic surgeons, dermatologists, gynecologists, primary care physicians, family practitioners, and physicians offering aesthetic treatments in non-medical offices, podiatrists, and other qualified practitioners. Cutera, Inc. was founded in 1998 and is headquartered in Brisbane, California.

266 Employees
Last Reported Date: 03/16/15
Founded in 1998

cutera inc (CUTR) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $907.5K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $504.3K
Compensation as of Fiscal Year 2014.

cutera inc (CUTR) Key Developments

Cutera, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter Ended June 30, 2015; Provides Financial Guidance for the Third Quarter and Fourth Quarter of 2015

Cutera, Inc. reported unaudited consolidated earnings results for the second quarter ended June 30, 2015. For the quarter, the company's net revenue was $22.56 million compared to $17.72 million a year ago. The growth has all been organic and fueled primarily by recently launched enlighten and excel HR products, as well as continued strong contributions from legacy excel V and the xeo platforms. American sales team, delivered particularly impressive 57% product revenue growth this quarter. Loss from operations was $1.93 million compared to $2.84 million a year ago. Loss before income taxes was $1.84 million compared to $2.7 million a year ago. Net loss was $1.889 million compared to $2.74 million a year ago. Basic and diluted loss per share was $0.13 compared to $0.19 a year ago. Net cash provided by operating actives was $1.38 million compared to net cash used in operating actives of $2.52 million a year ago. Acquisition of property, equipment and software was $271,000 compared to $44,000 a year ago. The company expects third quarter financial performance to be similar to that of the second quarter. The company expects to be cash neutral in the third quarter of 2015. The company expects to be profitability on a GAAP basis in the fourth quarter of 2015. The company expects generate cash in the fourth quarter of 2015.

Cutera, Inc. to Report Q2, 2015 Results on Aug 05, 2015

Cutera, Inc. announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on Aug 05, 2015

Cutera, Inc., Q2 2015 Earnings Call, Aug 05, 2015

Cutera, Inc., Q2 2015 Earnings Call, Aug 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CUTR:US $14.69 USD +0.06

CUTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
El.En. SpA €42.30 EUR -0.13
Lutronic Corp 41,500 KRW -1,050.00
PhotoMedex Inc $0.79 USD +0.005
Valeant Pharmaceuticals International Inc C$296.20 CAD -8.79
Zeltiq Aesthetics Inc $31.80 USD -0.47
View Industry Companies

Industry Analysis


Industry Average

Valuation CUTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.5x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CUTERA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at